KR20210056936A - 아데노바이러스 벡터를 포함하는 폐암 진단용 조성물 및 이의 용도 - Google Patents
아데노바이러스 벡터를 포함하는 폐암 진단용 조성물 및 이의 용도 Download PDFInfo
- Publication number
- KR20210056936A KR20210056936A KR1020200150172A KR20200150172A KR20210056936A KR 20210056936 A KR20210056936 A KR 20210056936A KR 1020200150172 A KR1020200150172 A KR 1020200150172A KR 20200150172 A KR20200150172 A KR 20200150172A KR 20210056936 A KR20210056936 A KR 20210056936A
- Authority
- KR
- South Korea
- Prior art keywords
- lung cancer
- gene
- promoter
- cells
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 75
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 74
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 74
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 26
- 239000013598 vector Substances 0.000 title claims description 45
- 239000000203 mixture Substances 0.000 title claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 92
- 210000004027 cell Anatomy 0.000 claims abstract description 81
- 239000003550 marker Substances 0.000 claims abstract description 26
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 230000008685 targeting Effects 0.000 claims abstract description 16
- 239000005090 green fluorescent protein Substances 0.000 claims abstract description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims abstract description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims abstract description 5
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 239000013603 viral vector Substances 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 24
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 17
- 101000651017 Homo sapiens Pulmonary surfactant-associated protein A2 Proteins 0.000 claims description 16
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 claims description 16
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 16
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 108091070501 miRNA Proteins 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 6
- 108010054624 red fluorescent protein Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 101150118602 SFTPA2 gene Proteins 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 18
- 108091007420 miR‐142 Proteins 0.000 abstract description 11
- 238000013399 early diagnosis Methods 0.000 abstract description 6
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 18
- 230000034994 death Effects 0.000 description 17
- 231100000517 death Toxicity 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 239000003580 lung surfactant Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 239000002679 microRNA Substances 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 108020003589 5' Untranslated Regions Proteins 0.000 description 5
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000013601 cosmid vector Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 3
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 108010082025 cyan fluorescent protein Proteins 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940066294 lung surfactant Drugs 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- 101150073145 SFTPC gene Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000713896 Spleen necrosis virus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108050002220 Green fluorescent protein, GFP Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 description 1
- 101001007738 Homo sapiens Neurexophilin-4 Proteins 0.000 description 1
- 101000583156 Homo sapiens Pituitary homeobox 1 Proteins 0.000 description 1
- 101000864780 Homo sapiens Pulmonary surfactant-associated protein A1 Proteins 0.000 description 1
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 101000632467 Homo sapiens Pulmonary surfactant-associated protein D Proteins 0.000 description 1
- 101000633617 Homo sapiens Thrombospondin-4 Proteins 0.000 description 1
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100027531 Neurexophilin-4 Human genes 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100030345 Pituitary homeobox 1 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- 102100030060 Pulmonary surfactant-associated protein A1 Human genes 0.000 description 1
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100029219 Thrombospondin-4 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 208000005266 avian sarcoma Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
도 2는 본 발명의 아데노바이러스의 구조를 모식화한 도이다.
도 3은 재조합 벡터의 암세포 특이적 발현 효과를 확인한 도이다.
염기서열 | 서열번호 | |
hSFTPA2 SpeⅠ 정방향(F) | GCGCACTAGTACTCCTCAATGGTTTGGGAT | 1 |
hSFTPA2 SpeⅠ 역방향(R) | ATATACTAGTGCTTCAGGCCTCCGGCTGGA | 2 |
hSFTPC SpeⅠ 정방향(F) | GCGCACTAGTATTGGCAGATTTGACCTCGT | 3 |
hSFTPC SpeⅠ 역방향(R) | GTGTACTAGTCTTGCTGCAGGTGCTATGCT | 4 |
Claims (25)
- SFTP(Surfactant Protein) 유전자의 프로모터, 표지 유전자 및 miR 142를 표적하는 염기서열을 포함하는 바이러스 벡터.
- 제 1항에 있어서, SFTP 유전자 프로모터는 SFTPA2(Surfactant Protein A2) 유전자 프로모터 또는 SFTPC(Surfactant Protein C) 유전자 프로모터인, 바이러스 벡터.
- 제 2항에 있어서, SFTPA2 유전자의 프로모터는 서열번호 5로 표시되는 염기서열을 포함하는, 바이러스 벡터.
- 제 2항에 있어서, SFTPAC 유전자의 프로모터는 서열번호 6으로 표시되는 염기서열을 포함하는, 바이러스 벡터.
- 제 1항에 있어서, 아데노바이러스 벡터인, 바이러스 벡터.
- 제 5항에 있어서, E3 영역 내에 표지 유전자 및 miR 142를 표적하는 염기서열을 포함하는, 바이러스 벡터.
- 제 5항에 있어서, E1 영역 내 핵산 서열의 결실을 포함하는, 바이러스 벡터.
- 제 5항에 있어서, SFTP 유전자의 프로모터가 아데노바이러스의 내재적 유전자와 작동 가능하게 연결된, 바이러스 벡터.
- 제 8항에 있어서, 아데노바이러스의 내재적 유전자는 E1a, E1b, L1, L2, E2, L3, L4, E3 또는 E4를 포함하는, 바이러스 벡터.
- 제 1항에 있어서, miR 142를 표적하는 염기서열은 miR-142-3p 표적서열인, 바이러스 벡터.
- 제 8항에 있어서, miR-142-3p 표적서열은 서열번호 7로 표시되는 염기서열을 포함하는, 바이러스 벡터.
- 제 1항에 있어서, 표지는 발색효소, 방사성 동위원소, 크로모포어(chromopore), 발광물질, 형광물질, 프로브 또는 택(tag)인, 바이러스 벡터.
- 제 12항에 있어서, 형광물질은 루시퍼라아제 (luciferase), 증강 녹색 형광 단백질 (enhanced green fluorescent protein, EGFP), 녹색 형광 단백질 (green fluorescent protein, GFP), 노랑 형광 단백질 (Yellow Fluorescent Protein, YFP), 적색 형광 단백질 (Red Fluorescent Protein, RFP) 또는 청색 형광 단백질 (cyan fluorescent protein, CFP)인, 바이러스 벡터.
- 제 1항에 있어서, 폐암세포에서 특이적으로 표지 유전자를 발현하는, 바이러스 벡터.
- 제 1항에 있어서, 서열번호 8 또는 9로 표시되는 염기서열을 포함하는, 바이러스 벡터.
- 제 1항의 바이러스 벡터를 포함하는, 폐암세포 검출용 조성물.
- 제 16항에 있어서, 폐암세포는 순환종양세포인, 폐암세포 검출용 조성물.
- 제 16항의 폐암세포 검출용 조성물을 포함하는 폐암 진단용 키트.
- 제 18항에 있어서, 폐암세포는 순환종양세포인, 폐암 진단용 키트.
- 개체로부터 분리된 시료에 제 16항의 폐암세포 검출용 조성물을 처리하는 단계를 포함하는, 폐암세포 검출 방법.
- 제 20항에 있어서, 시료는 혈액, 혈청, 혈장, 타액, 복수, 누액, 뇌척수액, 흉수, 활액, 림프, 또는 뇨인, 암세포 검출 방법.혈액, 양수, 혈장, 혈청, 정액, 골수, 뇨, 조직 생검 또는 세포로부터 단백질을 추출한 용액인, 폐암세포 검출 방법.
- 제 20항에 있어서, 폐암세포는 순환종양세포인, 폐암세포 검출 방법.
- 제 20항에 있어서, 시료 내 표지 유전자 발현 세포가 폐암세포인 것으로 판단하는 단계를 추가로 포함하는, 폐암세포 검출 방법.
- 1) 개체로부터 분리된 혈액에 제 16항의 폐암세포 검출용 조성물을 처리하는 단계;
2) 혈액 내 표지 유전자 발현 세포를 분리하는 단계; 및
3) 분리한 세포를 배양하는 단계를 포함하는, 순환폐암세포의 분리 및 배양 방법. - 1) 개체로부터 분리된 혈액에 제 16항의 폐암세포 검출용 조성물을 처리하는 단계;
2) 혈액 내 표지 유전자 발현 세포를 분리하는 단계; 및
3) 분리한 세포를 배양하는 단계를 포함하는, 폐암의 진단에 필요한 정보를 제공하는 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190143535 | 2019-11-11 | ||
KR20190143535 | 2019-11-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210056936A true KR20210056936A (ko) | 2021-05-20 |
KR102504463B1 KR102504463B1 (ko) | 2023-02-28 |
Family
ID=76142943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200150172A Active KR102504463B1 (ko) | 2019-11-11 | 2020-11-11 | 아데노바이러스 벡터를 포함하는 폐암 진단용 조성물 및 이의 용도 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102504463B1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012003287A2 (en) * | 2010-06-30 | 2012-01-05 | The Johns Hopkins University | Compositions and methods for detecting and quantifying circulating tumor cells ctcs |
KR20140049593A (ko) * | 2011-08-23 | 2014-04-25 | 도쿠리쯔 교세이 호진 이야쿠 키반 켄큐쇼 | 제한 증식형 아데노바이러스 |
-
2020
- 2020-11-11 KR KR1020200150172A patent/KR102504463B1/ko active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012003287A2 (en) * | 2010-06-30 | 2012-01-05 | The Johns Hopkins University | Compositions and methods for detecting and quantifying circulating tumor cells ctcs |
KR20140049593A (ko) * | 2011-08-23 | 2014-04-25 | 도쿠리쯔 교세이 호진 이야쿠 키반 켄큐쇼 | 제한 증식형 아데노바이러스 |
Non-Patent Citations (4)
Title |
---|
Dimitris Kouretas et al., Experimental Lung Research, 19:485-503, 1993.* * |
GenBank Accession No.AY090568(2002.04.10)* * |
Melissa Grageda et al., Exp. Lung Res., 41(2):93-102, 2015.* * |
Susan E. Kelly et al., The Journal of Biological Chemistry, 271(12):6881-6888, 1996.* * |
Also Published As
Publication number | Publication date |
---|---|
KR102504463B1 (ko) | 2023-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2762257C2 (ru) | Генная терапия для лечения гемофилии a | |
KR102390075B1 (ko) | 오르니틴 트랜스카르바밀라아제(otc) 결핍증의 치료에 유용한 조성물 | |
CN112375748B (zh) | 基于水疱性口炎病毒载体的新型冠状病毒嵌合重组疫苗及其制备方法与应用 | |
AU747847B2 (en) | A simplified system for generating recombinant adenoviruses | |
KR102528641B1 (ko) | Pah 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법 | |
KR101449587B1 (ko) | 장기 지속형 약물 제형 | |
CN101213203A (zh) | 在转录后水平调节核酸表达的方法和组合物 | |
CN112251464B (zh) | 一种基因点突变的诱导方法 | |
KR101591887B1 (ko) | 장기 지속형 약물 제형 | |
CN112941038A (zh) | 基于水疱性口炎病毒载体的重组新型冠状病毒及其制备方法与应用 | |
CN112088015A (zh) | 人乳头瘤病毒疫苗及其用途 | |
CN111748546B (zh) | 一种产生基因点突变的融合蛋白及基因点突变的诱导方法 | |
CN106957859A (zh) | 一种用于拯救麻疹病毒、重组麻疹病毒的系统以及方法 | |
CN107893083A (zh) | 一种人类肠道病毒d68型感染性克隆及其构建方法和应用 | |
EP1121441B1 (en) | Selectively replicating viral vectors | |
CN114107231B (zh) | 实现全脑突触后神经元胞体标记的重组腺相关病毒及其应用 | |
KR102504463B1 (ko) | 아데노바이러스 벡터를 포함하는 폐암 진단용 조성물 및 이의 용도 | |
CA2362970A1 (en) | Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy | |
CN107988253A (zh) | 一个人miRNA作为猪蓝耳病病毒抑制物的应用 | |
CN115261409A (zh) | 新型溶瘤腺病毒载体、由其包装的病毒及其应用 | |
KR20220050073A (ko) | 뇌 조직으로 유전자를 전달하기 위한 조성물 및 이의 용도 | |
CN114621929B (zh) | 一种抗肿瘤树突状细胞及其制备方法、表达载体及应用 | |
CN113774047B (zh) | 鱼源蛋白酶基因及其应用 | |
CN110461323A (zh) | 溶瘤病毒的增殖方法和抗肿瘤剂 | |
CA2395490A1 (en) | Repressible sterility of animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20201111 |
|
PA0201 | Request for examination | ||
PN2301 | Change of applicant |
Patent event date: 20201229 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211222 Patent event code: PE09021S01D |
|
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20220726 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20221128 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230223 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20230223 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |